Drug Profile
Research programme: human monoclonal antibodies - Patrys
Alternative Names: PAM-1; PAT-PA1Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator OncoMab GmbH
- Developer Patrys
- Class Monoclonal antibodies
- Mechanism of Action Fibroblast growth factor receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Adenocarcinoma
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Adenocarcinoma in Australia (Parenteral)
- 28 Jul 2010 Preclinical trials in Adenocarcinoma in Australia (Parenteral)